Close Menu
MarketForces AfricaMarketForces Africa
    What's Hot

    Seplat Energy Target Price Hikes to N17,588 at CardinalStone

    November 16, 2026

    Oando Soars Amidst Plan to Cure Negative Equity, Pay Dividend

    November 16, 2026

    S&P Casts Doubt on Nigeria’s 2029 Investment Grade Ambition – CSL

    November 16, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Seplat Energy Target Price Hikes to N17,588 at CardinalStone
    • Oando Soars Amidst Plan to Cure Negative Equity, Pay Dividend
    • S&P Casts Doubt on Nigeria’s 2029 Investment Grade Ambition – CSL
    • Money Market Rates Shift as Banking Liquidity Surplus Drops
    • XRP Rebounds as Dip Buyers Accumulate after Price Hits Multi-Year Low
    • Nigerian Treasury Bills Yields Ease as Investor Demand Strengthens
    • Lagos Targets $1trn Economy by 2052 – Sanwo-Olu
    • DMO to Offer N2trn in Nigeria Bonds as Benchmark Yield Eases
    • Home
    • About Us
    Facebook X (Twitter) Instagram LinkedIn WhatsApp TikTok Telegram
    MarketForces AfricaMarketForces Africa
    Subscribe
    Monday, November 16
    • Home
    • News
    • Analysis
    • Economy
    • Mobile Banking
    • Entrepreneurship
    MarketForces AfricaMarketForces Africa
    MarketForces Africa » Companies » Pfizer Earnings in Good Health after Vaccine Demand Boost

    Pfizer Earnings in Good Health after Vaccine Demand Boost

    Marketforces AfricaBy Marketforces AfricaMay 6, 2021 Companies No Comments3 Mins Read
    Pfizer Earnings in Good Health after Vaccine Demand Boost
    Share
    Facebook Twitter LinkedIn Pinterest Email Tumblr Reddit Telegram WhatsApp Copy Link

    Pfizer Earnings in Good Health after Vaccine Demand Boost

    Biopharmaceutical company, Pfizer jumps 3% on the back of COVID vaccine success, beating Q1 estimates by almost 50%. The company’s records Q1 adjusted earnings per share of $0.93, marking a year-over-year increase of almost 50% and surpassing analysts’ expectations of $0.77.

    Due to increased sales, the company’s revenue came in at $14.58 billion, up 44.6% from the same period last year and above expectations of $0.77.

    Pfizer’s coronavirus vaccine was the star of the show, with first-quarter sales of the shot making up around 24% of its overall revenue for the quarter at $3.5 billion.

    The Biopharm company received its vaccine authorization in the U.S. in December, and has since distributed millions of doses around the country with plans to deliver 300 million by the end of July.

    There has been some concern regarding the slowdown in vaccine rollouts that the U.S. is currently seeing as supply outstrips demand, but Pfizer CEO Albert Bourla dismissed fears, noting that it’s normal to see a slowdown once all the most willing have received the vaccine.

    The firm expects an increase in vaccinations one the FDA approves the shot for teens (expected to happen this month).

    Pfizer also massively increased its projected revenue from its COVID vaccine, now expecting revenue to hit $26 billion, a big jump from the $15 billion it projected back in February.

    By 2022, the company plans to have the capacity to produce 3 billion doses and is currently in talks with various governments about distribution strategy.

    Full year guidance got a lift as well, and Pfizer now expects adjusted diluted earnings of between $3.55 and $3.65 per share, up from the last forecast of $3.20 at the top end. Full year revenue is projected to come in at between $70.50 billion and $72.5 billion, up from its previous forecast of $61.4 at the top end.

    Pfizer shares have risen over 18% since March 2021, when the vaccine program really got underway, and the Pfizer vax is currently the most popular in the U.S. with 131 million people already receiving the shot, compared to 109 million for Moderna, and fewer than 8 million for J&J. Go Pfizer.

    “I am extremely proud of the way we have begun 2021, delivering strong financial results in the first quarter,” said the company’s CEO, Albert Bourla, in a statement.

    Crude Oil Prices Plunge over Demand Uncertainty

    “Even excluding the growth provided from, our revenues grew 8% operationally, which aligns with our stated goal of delivering at least a 6% compound annual growth rate through 2025.”

    Pfizer Earnings in Good Health after Vaccine Demand Boost

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Marketforces Africa
    • Website
    • Facebook
    • X (Twitter)
    • Instagram
    • LinkedIn

    MarketForces Africa, a Financial News Media Platform for Strategic Opinions about Economic Policies, Strategy & Corporate Analysis from today's Leading Professionals, Equity Analysts, Research Experts, Industrialists and, Entrepreneurs on the Risk and Opportunities Surrounding Industry Shaping Businesses and Ideas.

    Keep Reading

    Oando Soars Amidst Plan to Cure Negative Equity, Pay Dividend

    Investors Value Access Holdings 54.375bn Outstanding Shares at N1.47trn

    FirstHoldco Falls to N4.68trn as Investors Continue to Exit Positions

    Alternative Bank Appoints Gul Khan as MD/CEO

    Custodian Investment at N63: Is a N100 Target Within Reach?

    Dangote Cement Withdraws from London Stock Exchange Listing

    Add A Comment

    Comments are closed.

    Editors Picks

    Seplat Energy Target Price Hikes to N17,588 at CardinalStone

    November 16, 2026

    Oando Soars Amidst Plan to Cure Negative Equity, Pay Dividend

    November 16, 2026

    S&P Casts Doubt on Nigeria’s 2029 Investment Grade Ambition – CSL

    November 16, 2026

    Money Market Rates Shift as Banking Liquidity Surplus Drops

    November 16, 2026

    XRP Rebounds as Dip Buyers Accumulate after Price Hits Multi-Year Low

    November 15, 2026
    Latest Posts

    Oando Soars Amidst Plan to Cure Negative Equity, Pay Dividend

    November 16, 2026

    Investors Value Access Holdings 54.375bn Outstanding Shares at N1.47trn

    November 11, 2026

    FirstHoldco Falls to N4.68trn as Investors Continue to Exit Positions

    November 11, 2026

    Alternative Bank Appoints Gul Khan as MD/CEO

    November 11, 2026

    Custodian Investment at N63: Is a N100 Target Within Reach?

    November 10, 2026

    Subscribe to News

    Get latest news from MarketForces Africa...

    Advertisement
    Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

    News

    • World
    • Politics
    • Economy
    • Business
    • Opinions
    • Fintech
    • Science & Technology

    Company

    • About us
    • Advertising
    • Classified Ads
    • Contact Info
    • Editorial Policy

    Services

    • Subscriptions
    • Research
    • Due Diligence
    • Newsletters
    • Sponsored News
    • Work With Us

    Subscribe to Updates

    Subscribe to updates from MarketForces Africa, an independent financial news service provider.

    © 2026 MarketForces Africa. All rights reserved.
    • Privacy Policy
    • Terms
    • Accessibility

    Type above and press Enter to search. Press Esc to cancel.